Trial Profile
Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastrointestinal cancer; Liver cancer
- Focus Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 20 Aug 2021 Protocol of study has been amended to add phase 2 study with the primary objective of defining the ORR of the combination
- 20 Aug 2021 Results published in the Cancer
- 27 Feb 2020 Status changed from recruiting to discontinued.